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Abstract: Co-infection of human immunodeficiency virus (HIV) and neurosyphilis (NS) has become a rising trend, 
but the extent of brain damage associated with the concomitant infections remains unknown. Proton magnetic 
resonance spectroscopy (1H-MRS) can evaluate metabolic changes underlying early brain infections. 25 syphilitic 
patients (7 HIV-positive with NS; 6 HIV-positive without NS; 5 HIV-negative with NS; 7 non-HIV, non-NS) and 17 
healthy controls (HC) underwent single-voxel 1H-MRS in the bilateral hippocampi. Absolute concentrations of major 
metabolites were measured using a 3T MRI scanner. No significant structural abnormality was detected in all pa-
tients. However, metabolic changes were found in the left hippocampus of both the HIV-positive and NS subgroups, 
showing significantly higher choline (Cho), creatine (Cr) and myo-inositol (mI) compared to HC. In the right hippo-
campus, HIV-positive subgroup showed significantly higher Cr and reduced NAA, while NS subgroup only showed 
significantly reduced NAA compared to HC. The non-HIV, non-NS syphilitic subgroup showed no significant difference 
compared to HC. Substantial metabolic changes occurred in bilateral hippocampi in HIV and NS co-infections. NAA 
reduction might represent early neuronal damage, while mI/Cho elevation reflects gliosis/inflammatory changes. 
1H-MRS could serve as a non-invasive tool to triage patients suspected of NS for lumbar puncture in non-HIV syphi-
litic patients.
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Introduction
Central nervous system (CNS) is commonly 
involved in the early stage of human immuno-
deficiency virus (HIV) infection. HIV can invade 
the brain directly, involving the glial cells and 
neurons, causing subclinical encephalitis [1-3]. 
After the onset of acquired immune deficiency 
syndrome (AIDS), approximately 10-15% of the 
AIDS patients will develop HIV-associated 
dementia complex, characterized by cognitive, 
behavioral, and motor dysfunction [4]. The early 
initiation of antiretroviral therapy reduced rates 
of sexual transmission of HIV and clinical 
events such as early occurrence of pulmonary 
tuberculosis, severe bacterial infection or 
death [5]. However, with the advent of highly 
active antiretroviral therapy (HAART), rates of 
syphilis and other sexually transmitted diseas-
es (STDs) have risen among men who have sex 
with men (MSM), reflecting a general increase 
in unsafe sexual behavior [6, 7]. 
Another common sexually transmitted disease 
(STD) with CNS invasion is neurosyphilis (NS), 
being caused by the spirochete Treponema pal-
lidum. About 1/3 of patient with early syphilis 
have invasion of the treponemes in the cerebro-
spinal fluid (CSF), regardless of their HIV status 
[7]. There is no single reliable diagnosis of NS 
due to a lack of infallible laboratory test, obscu-
rity in clinical symptoms and the possibility of 
giving both false positive and false negative 
results in CSF-Venereal Disease Research 
Laboratory (CSF-VDRL) test [8-10]. 
The increased occurrence of NS with HIV infec-
tion has been reported in previous studies [11-
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14]. The reported prevalence of NS in HIV 
infected patients can be as high as 23.5-40%, 
compared to 10% in HIV seronegative patients 
with untreated syphilis. Co-infection with NS in 
HIV patients has adverse effects on clinical out-
come and prognosis [15]. Complex interactions 
between HIV and NS had been reported, im- 
pacting clinical manifestations, diagnosis, and 
treatment of syphilis [7, 16]. Some studies sug-
gested that HIV-related immunocompromise 
has the potential to promote syphilitic involve-
ment of the CNS [6, 7, 17, 18]. In addition, dis-
order of the humoral immune response to 
Treponema pallidum in HIV patients can pro-
duce confusing results in serological tests for 
NS [18, 19]. Nevertheless, one recent study 
[20] showed that under HAART treatment, the 
effect of HIV on serologic response to syphilis 
treatment was likely minimal or absent. 
Up-to-date, there was only one neuroimaging 
study on HIV positive (HIV+) and HIV negative 
(HIV-) patients with NS [12], though no compari-
son can be made due to the limited number of 
only 3 HIV- NS patients in contrast to 32 HIV+ 
NS patients. The authors suggested that pres-
ence of vascular occlusive disease in HIV+ 
patients should prompt the appropriate testing 
for NS. 
There are recent retrospective reports on 
Magnetic Resonance Imaging (MRI) findings of 
brain in NS patients, including T2 hyperintensi-
ty in mesial temporal lobes and other less spe-
cific regions, and atrophy especially in temporal 
and frontal lobes [21-24]. In particular, some 
studies reported resolution of T2 hyperintensity 
after treatment for NS [22, 24]. The pathologi-
cal basis of such changes in MRI brain remains 
to be confirmed.
Interestingly, viral loads of HIV had been report-
ed to be particularly high in the hippocampus 
[25]. A prior functional MRI (fMRI) study 
revealed that compared to HIV- women, HIV+ 
women showed decreased activation during 
encoding, and increased activation during rec-
ognition in bilateral hippocampi in a delayed 
verbal episodic memory task, suggesting HIV 
might affect the functional integrity of the 
medial temporal system [26]. Another fMRI 
study of well-educated HIV+ men demonstrat-
ed reduced signal intensity in right posterior 
hippocampus and right inferior frontal gyrus, 
during encoding of scenes [27]. All these find-
ings suggested HIV functionally impacted the 
hippocampal system.
Proton magnetic resonance spectroscopy (1H-
MRS) can measure metabolite levels by using 
proton signals from the metabolites and has 
been employed extensively in HIV infection. A 
summary of these studies was tabulated in 
Table 1. Many studies found lowered N-acetyl-
aspartate/creatine (NAA/Cr), or N-acetyl-as- 
partate/choline (NAA/Cho) or both in the sub-
cortical white matter of asymptomatic HIV+ 
patients [28-30], and in AIDS dementia com-
plex (ADC) patients [1, 28, 31-33]. These reduc-
tions might represent early neuronal damage 
without gross anatomical abnormalities. Other 
studies using absolute quantification also con-
firmed lower absolute concentrations of NAA in 
the white matter of ADC [34], HIV+ patients 
with cognitive impairment [35], asymptomatic 
chronic HIV+ [36], and in the basal ganglia of 
HIV dementia [37]. Interestingly, a recent 
1H-MRS study using absolute quantification 
reported that NAA and Glx (glutamine plus glu-
tamate) concentrations were significantly re- 
duced in the cortical gray matter of early HIV-
infected subjects, but not in the deep white 
matter, further indicating HIV might cause neu-
ronal dysfunction after infection [36]. 
Prior studies also reported elevated myo-inosi-
tol (mI) or mI/Cr level in frontal white matter 
and/or basal ganglia of HIV-associated demen-
tia patients [1, 31, 33, 37]. These elevations 
might be due to increased glial activity. Another 
metabolite which is also related to glial cells is 
choline (Cho). In previous studies in asymptom-
atic HIV patients, deep white matter Cho or 
Cho/Cr level was found to be increased [30, 35, 
38] or have no change [28, 29], while elevated 
Cho or Cho/Cr was seen in the ADC stage [1, 
28, 33-35, 38]. Elevated Cho might be 
explained by cellular injury and glial prolifera-
tion as higher concentration of Cho was found 
in glial cells [39]. 
Although 1H-MRS may serve as a noninvasive 
mean of determining neuronal injury and neuro-
logic dysfunction in HIV patients, and monitor-
ing of HAART [40, 41], there is a paucity of lit-
erature on 1H-MRS study in NS. Hence, the 
potential role of 1H-MRS in NS remains to be 
elucidated, such as detection of any early brain 
injury or assessment of treatment response of 
NS in HIV patients (since confusing results in 
serological tests might occur in these patients).
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Table 1. Summary of previous studies using proton magnetic resonance spectroscopy (1H-MRS) to measure metabolite levels in HIV infection
Study Title/Purpose Methodology (sample size/region-of-interest/ 
quantification method)
Results
[1] Clinical severity of HIV-1 cognitive 
motor complex
20 HIV-MCMD, 34 HIV-dementia, 29 HC/Frontal cortex, 
frontal white matter, basal ganglia/Absolute (corrected 
for CSF)
3 groups differ in mI, Cho in frontal WM
HIV-CMC: ↑mI and ↑Cho with ↑ADC stage and ↓NAA in moderate to severe ADC stage
CD4 count, CSF viral load correlate with metabolites
HIV-dementia scale correlate with metabolites
↓NAA/Cr in frontal WM of early HIV-CMC due to slight but non-sig ↑Cr with slight ↓NAA
[28] HIV-related metabolic abnormali-
ties in the brain
12 ADC, 11 HIV+ asymptomatic, 10 HC/Parietooccipital, 
bioccipital/Ratio
ADC- brain atrophy and diffuse white matter, ADC vs HC:
↓NA/Cr, ↑mI/Cr, ↑Cho/Cr
HIV+ vs HC:
↓NA/Cr, ↑mI/Cr , no change Cho/Cr
[29] Neurologically asymptomatic HIV-
infected patients
30 asymptomatic HIV, 13 HC/Centrum semiovale (both 
sides) & thalamus/Ratio
↓NAA/Cr & ↓NAA/Cho in centrum semiovale and thalami
↓NAA/Cr more in WM than GM
trend towards correlation between CD4 and NAA/Cr
[30] Neurologically asymptomatic HIV- 
infected patients
20 asymptomatic HIV, 32 HC/Frontal lobe WM/Ratio HIV+: ↓NAA/Cho, ↓NAA/H2O & Cr/H2O ; ↑Cho/Cr & mI/Cr
significant correlation of CD4 and NAA/H2O
[31] Multi-centre study of two MRS 
techniques in individuals with HIV 
dementia
20 HIV+, 3 HIV- HC/Frontal WM (SVS), mesial frontal GM 
(MRSI)/Ratio
HIV+ with psychomotor slowing compared to HIV+ without psychomotor slowing: ↑mI/Cr in frontal WM 
(SVS), ↑Cho/Cr in mesial frontal GM (MRSI)
HIV+ with dementia compared to HIV+ without dementia: ↓NAA/Cho in mesial frontal GM (MRSI)
[32] HIV-infected individuals 7 ADC, 8 HIV+, 7 HC/Frontal WM and GM/Ratio HIV+ vs HC: ↑mI/Cr in WM
ADC vs HC/HIV+: ↓NAA/Cr in GM
Correlation with neuropsychiatric tests: poor neuropsychiatric performance with ↓NAA/Cr in GM & WM
poor neuropsychiatric performance with ↑mI/Cr in WM
[33] AIDS Dementia Complex: 38 ADC, 18 HC/Midline posterior parietal cortex (GM), 
mid frontal CS (WM), basal ganglia (GM)/Ratio
ADC vs HC: ↓NAA/Cr in frontal WM, not parietal GM
ADC vs HC: ↑Cho/Cr & ↑mI/Cr in basal ganglia and WM
[34] AIDS Dementia Complex 7 ADC, 7 HC/11 regions (CSF contamination in caudate)/
Absolute (arbitrary unit)
↓NAA, ↑Cho in WM
[35] Cognitively and clinically asymp-
tomatic HIV patients
70 HIV+ (varying severities), 30 HC/2 caudate, 2 lenticu-
lar nuclei, 2 thalami/Absolute
HIV+: ↑subcortical Cho, ↓subcortical NAA only in cognitively impaired HIV+
subcortical NAA correlate with neuropsychiatric but not CDC stage
high thalamic Cho associated with ↓CD4
[36] Early HIV infection 8 early HIV, 9 HC, 10 chronically HIV-infected asymp-
tomatic/Superior frontal GM, centrum semiovale WM/
Absolute
↓NAA & ↓Glx cortical gray matter of HIV+ subjects
↓NAA centrum semiovale of chronic HIV+
↓NAA frontal cortex with early infection associated with ↑CD8
[37] Brain metabolism & cognitive 
impairment in HIV infection:
86 asymptomatic HIV: 21 normal cognition, 31 MCI, 34 
HAD/Frontal WM & basal ganglia/Ratio
Frontal WM Glx & Glx/Cr↓ in HAD vs MCI/NC
Frontal WM mI & mI/Cr↑ in HAD vs MCI/NC
Basal ganglia NAA↓ in HAD vs MCI/NC
Significant correlation between Glu/Glx, NAA with neuropsychiatric tests
[38] HIV+ patients before the onset of 
AIDS dementia complex
20 HIV+ (varying stages of ADC), 10 HC/GM precuneus, 
both hemispheres/Ratio
↓NAA/Cr with advanced dementia
↑Cho/Cr with early HIV infection or CD4>200/µl
↑Cho before ↓NAA, before MRI abnormalities and dementia onset
[40] HAART reverses brain metabolite 
abnormalities in mild HIV de-
mentia
16 HIV-CMC (before & after HAART), 15 HC/Frontal lobe 
(GM & WM), basal ganglia/Absolute and Ratio
Reversal of ↑Cho/Cr in midfrontal cortex by 8.0%, basal ganglia by 14.7%
Reversal of ↑mI/Cr & mI in basal ganglia by 14.1% & 11.8% respectively
Normalization of mI in frontal WM, change of mI correlate with CD4 (r=-0.67), and ADC stage
[41] Change in brain MRS after treat-
ment during acute HIV infection
31 acute HIV+, 26 chronic HIV+, 10 HIV- HC/Left frontal 
WM, basal ganglia, midline FGM, occipital GM/Ratio
acute HIV vs HC/chronic HIV: ↑Cho/Cr in basal ganglia and occipital GM
Key: ADC, AIDS dementia complex; Cho, choline; Cr, creatine; Glx, glutamate and glutamine complex; GM, grey matter; HAART, highly active antiretroviral therapy; HAD, HIV-associated dementia; HC, healthy control; HIV-CMC, HIV-cognitive 
motor complex; HIV-MCMD, HIV-minor cognitive motor disorder; MCI; mild cognitively impaired; mI, myo-inositol; MRSI, magnetic resonance spectroscopic imaging; NA, N-acetyl compounds; NAA, N-acetyl-aspartate; NC, normal cognition; SVS, 
single-voxel spectroscopy; WM, white matter; ↑, significant increase; ↓, significant decrease.
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Table 2. Clinical profiles of syphilitic patients recruited from local sexual health clinics
Patient (Sex/Age/clinical features) HIV status [Duration between 
Diagnosis of HIV and MR scan]
NS 
status
CD4 cell 
count (μL)
Viral Load (copies/ml)
Syphilis stage (Duration of treatment for known stage 
of syphilis between start of treatment and MRI scan)
1 (M/38) Positive [2 years] Negative 237 <75 (on HARRT for 1.5 years) Early latent (not on treatment)
2 (M/28/genital warts) Positive [1 month] Positive 493 37000 NS (not on treatment)
3 (M/61) Positive [1 month] Positive 243 36000 NS (not on treatment)
4 (M/60) Positive [2 months] Positive 436 270000 NS (on treatment for 1 month)
5 (M/60) Positive [4 months] Negative 184 320000 Late latent (on treatment for 2 months)
6 (M/24) Positive [1 month] Positive 320 110000 NS (not on treatment)
7 (M/42) Positive [20 years] Positive 985 <75 (on HARRT for 13 years) NS (not on treatment)
8 (M/47) Positive [<1 month] Negative 258 45000 Late latent (not on treatment)
9 (M/38/genital warts) Positive [1 month] Positive 222 290000 NS (not on treatment)
10 (M/47) Positive [2 months] Negative 58 790000 (on HARRT for 7 days) Late latent (not on treatment)
11 (M/29) Positive [2 months] Negative 227 150000 Secondary (not on treatment)
12 (M/32) Positive [1 month] Negative 385 34000 Late latent (not on treatment)
13 (M/43) Positive [3 months] Positive 325 180000 NS (not on treatment)
14 (M/59/raised VDRL titer after treatment) Negative Positive - - NS (on treatment for 1 month)
15 (F/55/nonspecific genital infection, right 
intermediate uveitis)
Negative Positive - - NS (on treatment for 13 months)
16 (M/50/bilateral scleritis) Negative Positive - - NS (not on treatment)
17 (M/62/uveitis) Negative Positive - - NS (not on treatment)
18 (M/64/dementia) Negative Positive - - NS (on treatment for 2 months)
19 (F/35/right vitritis) Negative Negative - - Late latent (not on treatment)
20 (M/66/sensorineural hearing loss) Negative Negative - - Late latent (not on treatment)
21 (F/68/persistent high titer VDRL after 
treatment)
Negative Negative - - Late latent (on treatment for 13 months)
22 (F/59/bilateral anterior uveitis) Negative Negative - - Late latent (not on treatment)
23 (M/69/right optic neuritis) Negative Negative - - Late latent (on treatment for 8 months)
24 (F/60/uveitis) Negative Negative - - Late latent (not on treatment)
25 (M/58/bilateral optic atrophy,  gonor-
rhea)
Negative Negative - - Late latent (not on treatment)
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In this study, we evaluated a cohort of syphilitic 
patients referred from several sexual health 
clinics, suspected of NS due to positive VDRL 
titer after treatment, HIV status or neurological 
manifestations. We attempted 1) to detect 
early metabolic changes in the hippocampi of 
HIV+, NS positive (NS+) and non-HIV, non-NS 
patient subgroups, and 2) to evaluate the 
potential role of 1H-MRS in detecting NS in 
patients with reactive syphilis serology, with 
and without co-infection with HIV.
Methods
Subjects
Twenty-seven syphilitic serology positive pati- 
ents with indications for lumbar puncture (i.e. 
neurological manifestations, co-infection with 
HIV, or persistently raised VDRL titer after treat-
ment) and consented to have MRI done, were 
recruited from several sexual health clinics dur-
ing the period from December 2010 to October 
2012. All patients were scanned within two 
months (range- 2 to 57 days) after the lumbar 
puncture. 
The clinical profiles of the syphilitic patients 
were listed in Table 2 (except 2 patients in 
Group C). In this cohort of 25 syphilitic patients, 
there were 12 patients with NS, 11 with late 
latent, 1 with early latent and 1 with secondary 
syphilis.
Group A: There were 13 male HIV+ patients 
(mean age: 42.23±12.52 years; 7 with NS and 
6 without NS). HIV+ patients were identified by 
two subsequent enzyme-linked immunoassay 
(ELISA) tests and confirmed with Western Blot. 
Their plasma viral loads and CD4 cell counts 
were tabulated in Table 2. Three out of the thir-
teen HIV+ patients were receiving HAART, and 
one of them for less than 7 days. 
Group B: There were 12 NS+ patients (mean 
age: 48.83±13.71 years; 7 with HIV and 5 with-
out HIV). The diagnosis was made strictly 
according to the 2010 Sexually Transmitted 
Diseases Treatment Guidelines by the Centers 
for Disease Control and Prevention (CDC) [42]. 
Four patients were under treatment of NS at 
time of MRI scanning; 3 for 2 months or less, 
and 1 for 13 months.
Group C: There were 9 patients who were nega-
tive for both HIV and NS. One patient had 
dementia and one had poor-quality MR spec-
tra, and both were excluded in the 1H-MRS data 
analysis. Hence, only 7 patients with mean age 
of 59.29±11.60 years were included in this 
group. They were all late latent cases and only 
2 had been treated at time of MRI scanning. 
17 healthy controls (Group D) with mean age of 
39.59±13.87 years were recruited from the 
university staff and students. They were 
screened and excluded for high systolic blood 
pressure (>140 mmHg), previous cerebrovas-
cular events and claustrophobia. They did not 
have any history of neurological disease and 
were not taking any psychiatric drug. They 
attended the university health clinic for routine 
check-up, which included blood pressure 
checking as well as clinical and physical exami-
nation by a registered medical practitioner. No 
memory deficit was detected on assessment.
All patients and healthy controls gave their 
informed consent to participate and the study 
was approved by the local Institutional Review 
Board.
Data acquisition
All MR scans were performed using a 3T scan-
ner (Achieva 2.6.3, Philips Healthcare, Best, 
The Netherlands). A sensitivity encoding (SEN- 
SE)-head-8-coil, was used. 
MRI: A standardized T1W 3D volumetric Fast 
Field Echo (FFE) sequence was employed with 
the following imaging parameters: repetition 
time TR/TE=7.0/3.2 ms, voxel size=1 x 1 x 
1mm3, field of view (FOV)=256 x 256 x 167 
mm3, reconstruction matrix=256, turbo field 
echo (TFE) factor=240. Images acquired from 
T1W 3D FFE were employed for the positioning 
of single-voxel-spectroscopy (SVS) for 1H-MRS. 
Axial T2-weighted fast spin-echo images (TR/
TE=3000/80 ms, flip angle 90°, slice thickness 
5 mm, ETL 16) and T2-weighted fluid-attenuat-
ed inversion-recovery (FLAIR) fast spin-echo 
images (TR/TE=11000/120 ms, slice thick-
ness 2.5 mm, reconstruction matrix 512) were 
also acquired to exclude structural abnormali-
ties. T1 and T2 images were interpreted by an 
experienced neuroradiologist (HKFM), who was 
blinded to the HIV and NS status of the patients. 
Susceptibility weighted images (SWI) were 
obtained using 2 mm slice thickness, FOV=230 
x 201 x 135 mm3, TR/TE=28/23 ms. Magnetic 
1H-MRS in HIV and NS co-infection
88 Am J Nucl Med Mol Imaging 2015;5(1):83-94
resonance angiography (MRA) was also per-
formed using 2.5 mm slice thickness, FOV=230 
x 201 x 137 mm3, TR/TE=11000/230ms, inver-
sion time=2800ms and flip angle 20°.
1H-MRS: Point resolved spectroscopy (PRESS) 
was used as the volume selection method for 
the region-of-interest (ROI) and excitation for 
water suppression. Scanning parameters are: 
TR/TE=2000/39 ms, number of signals aver-
aged (NSA)=128, phase cycles=16, spectral 
width=2000 Hz with spectral resolution of 1.95 
Hz per point, free induction decay=1024. For 
shimming, pencil-beam-auto was employed. 
Voxels of size 2.5 x 1.5 x 1 cm3 were 
placed in the left and right hippocampi. 
The whole scan time was approximate-
ly 60 minutes.
Data analysis
MRI: T2-weighted and FLAIR images 
were interpreted by an experienced 
neuroradiologist (HKFM), with scores 
based on the semi-quantitative Faze- 
kas-scale [43]. SWI and MRA were also 
interpreted to look for hemorrhages 
and vascular stenosis respectively. 
Cortical atrophy was determined by 
visual inspection [12]. 
1H-MRS: In this study, two 1H-MRS files 
were generated simultaneously by our 
scanner. One file was the actual (sup-
pressed) 1H-MRS data, the other file 
was the unsuppressed water signal 
intensity 1H-MRS file. For our absolute 
concentration calculation, the unsup-
pressed water signal intensity was 
used as internal reference. 
The 1H-MRS spectra were processed 
with an offline java-based version of 
jMRUI (4.0) software. Spectrum simula-
tion of various metabolites was com-
pleted using the built-in NMR-SCOPE. 
Signal amplitudes were determined 
using QUEST (quantification based on 
quantum estimation). The unsup-
pressed water signal was also mea-
sured using jMRUI. Cho, Cr, mI and NAA 
were measured and quantified as 
described in a previous study [44]. 
Examples of spectra in jMRUI of a HIV+ 
patient and a healthy control were illus-
trated in Figures 1 and 2 respectively.
Figure 1. Example of spectra in jMRUI of a 29-year-old HIV+ without 
NS subject’s left hippocampus, simulated spectrum using QUEST 
(A), spectrum obtained from the subject (red) superimposed on 
the simulated spectrum (blue) from QUEST (B).
Figure 2. Example of spectra in jMRUI of a 25-year-old healthy 
control’s left hippocampus, simulated spectrum using QUEST (A), 
spectrum obtained from the subject (red) superimposed on the 
simulated spectrum (blue) from QUEST (B).
Image processing: In order to account for the 
variations in water content in gray matter (GM), 
white matter (WM) and CSF, Voxel-Based 
Morphometry (VBM) was used to determine the 
GM, WM and CSF composition within the voxel 
of each of the two regions investigated, as 
detailed in our previous publications [44, 45]. 
Statistical analysis: SPSS 20.0 was employed 
for statistical analysis. Two-samples t-test was 
used to compare the metabolite concentra-
tions and metabolic ratios between Groups A, B 
and C with normal controls (Group D). Since 
Groups C and D differed significantly in age, 
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age was adjusted using a linear regression 
model. The level of significance was set at 0.05.
Results
Immunologic data 
The immunologic data of the HIV+ patients 
were tabulated in Table 2. HIV+ patients had a 
median CD4 cell count of 258 cells/uL and 
median plasma viral load of 110,000 copies/
ml. Of all the thirteen HIV+ patients, three 
patients were receiving HAART. One patient just 
started HAART for less than 7 days had plasma 
viral load of 790,000 copies/ml and CD4 count 
of 58 cells/uL. Other two patients who were 
both receiving HAART for more than 1.5 years 
had undetectable viral load levels (<75 copies/
ml) and an average CD4 cell count of 611 cells/
uL. In view of limited sample size, correlative 
study between immunologic data and metabo-
lite levels was not performed.
MRI findings of patients from sexual health 
clinics 
The MRI findings of the patients were tabulated 
in Table 3. The structural images of all patients 
did not reveal any cerebral infarct (except 2 
patients in Group C), and showed only non-spe-
cific punctate T2/FLAIR signal abnormalities in 
the subcortical and deep white matter of the 
cerebral hemispheres (Fazekas’ score- 0 or 1). 
1 patient in Group B and 2 patients in group C 
had confluent signal abnormalities (Fazekas’ 
score- 2 or 3). Only 3 patients showed moder-
ate to marked cortical atrophy, with 1 patient 
from each patient group. None of the patients 
showed arteritis in MRA.
1H-MRS
The mean absolute metabolite concentrations 
and metabolite ratios of the healthy controls, 
HIV+ patients, NS+ patients and non-HIV, non-
NS patients were tabulated in Table 4.
Mean absolute concentrations of metabolites 
and metabolite ratios in HIV+ patients 
In the left hippocampus, HIV+ patients showed 
significantly higher Cho (p=0.023), Cr (p=0.018) 
and mI (p=0.005) compared to normal con-
trols. In the right hippocampus, HIV+ patients 
showed significantly higher Cr (p=0.029), lower 
Table 3. MRI findings of syphilitic patients recruited from local sexual health clinics
Patient 
(Sex/Age)
T2/FLAIR scores and Hyper-
intensity Cerebral infarcts Cortical atrophy Hemorrhage
1 (M/38) 1 Punctate few Nil Nil Nil
2 (M/28) 0 Nil Nil Nil Nil
3 (M/61) 1 Few punctate Nil Mild Nil
4 (M/60) 1 Few punctate Nil Minimal to mild Nil
5 (M/60) 1 Multiple punctate Nil Moderate Nil
6 (M/24) 0 Nil Nil Nil Nil
7 (M/42) 0 Nil Nil Nil Nil
8 (M/47) 0 Nil Nil Minimal Nil
9 (M/38) 0 Nil Nil Minimal Nil
10 (M/47) 1 Scattered punctate Nil Minimal Nil
11 (M/29) 1 Few punctate Nil Nil Nil
12 (M/32) 1 Few punctate Nil Nil Nil
13 (M/43) 1 Few punctate Nil Nil Nil
14 (M/59) 1 Few punctate Nil Nil Nil
15 (F/55) 0 Nil Nil Nil Nil
16 (M/50) 0 Nil Nil Mild Nil
17 (M/62) 0 Nil Nil Nil Nil
18 (M/64) 3 Multiple punctate and confluent Nil Marked Nil
19 (F/35) 0 Nil Nil Nil Nil
20 (M/66) 2 Punctate and early confluent Bilateral centrum semiovale, pons moderate to severe Nil
21 (F/68) 1 Multiple punctate Nil Mild to moderate Cavernomas
22 (F/59) 2 Punctate and early confluent Left insula, bilateral putamen Minimal Microbleeds
23 (M/69) 1 Scattered punctate Nil Mild Left cerebellar vascular malformation
24 (F/60) 1 Scattered punctate Nil Minimal Nil
25 (M/58) 1 Scattered punctate Nil Mild Scattered microbleeds
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Table 4. Mean concentrations and ratios of various metabolites showing statistical results between different cohorts
[Cho] [Cr] [NAA] [mI] Cho/Cr NAA/Cr mI/Cr Cr/Cho NAA/Cho mI/Cho
Hippo-
campus
Mean Con-
centration 
(mmol/kg) 
Mean Con-
centration 
(mmol/kg)
Mean Con-
centration 
(mmol/kg)
Mean Con-
centration 
(mmol/kg)
Mean 
ratio
Mean
ratio
Mean
ratio
Mean
ratio
Mean
ratio
Mean
ratio
Normal 
Control 
(n=17)
Left 0.64± 
0.10
6.11± 
0.61
15.15± 
2.26
0.07± 
0.12
0.11± 
0.02
2.51± 
0.49
0.01± 
0.02
9.73± 
1.49
24.05± 
4.09
0.11± 
0.16
Right 1.28± 
0.13
8.44± 
1.10
11.68± 
1.51
0.16± 
0.22
0.15± 
0.02
1.41± 
0.28
0.02± 
0.02
6.72± 
0.93
9.29± 
1.88
0.12± 
0.16
Compared to normal control using two-samples t-test
HIV+ 
(n=13)
Left 0.72± 
0.07
0.023
*,↑
6.84± 
0.97
0.018
*,↑
15.17± 
1.72
0.979 0.24± 
0.19
0.005
**,↑
0.11± 
0.02
0.732 2.26± 
0.39
0.138 0.04± 
0.03
0.004
**,↑
9.55± 
1.50
0.751 21.15± 
2.16
0.028
*,↓
0.34± 
0.25
0.006
**,↑
Right 1.34± 
0.22
0.350 9.52± 
1.48
0.029
*,↑
10.69± 
0.96
0.049
*,↓
0.37± 
0.39
0.074 0.14± 
0.02
0.177 1.15± 
0.22
0.010
*,↓
0.04± 
0.04
0.067 7.23± 
1.36
0.233 8.18± 
1.48
0.092 0.29± 
0.34
0.076
NS+ 
(n=12)
Left 0.76± 
0.09
0.005
**,↑
7.19± 
1.10
0.002
**,↑
14.71± 
3.18
0.664 0.24± 
0.17
0.003
**,↑
0.11± 
0.02
0.771 2.09± 
0.53
0.037
*,↓
0.03± 
0.02
0.003
**,↑
9.64± 
1.77
0.884 19.63± 
4.33
0.009
**,↓
0.31± 
0.20
0.005
**,↑
Right 1.28± 
0.21
0.947 9.30± 
1.62
0.097 10.53± 
0.96
0.029
*,↓
0.30± 
0.20
0.085 0.14± 
0.02
0.071 1.16± 
0.20
0.013
*,↓
0.03± 
0.02
0.074 7.34± 
1.17
0.1244 8.37± 
1.18
0.147 0.23± 
0.14
0.048
*,↑
nonHIV, 
nonNS 
(n=7)
Left 0.73± 
0.10
0.215 6.04± 
1.73
0.525 14.71± 
3.54
0.516 0.19± 
0.16
0.358 0.13± 
0.03
0.049
*,↑
2.49± 
0.55
0.942 0.03± 
0.02
0.167 8.23± 
2.07
0.116 20.05± 
4.51
0.094 0.26± 
0.19
0.372
Right 1.30± 
0.15
0.612 9.34± 
2.53
0.142 10.44± 
2.20
0.307 0.40± 
0.27
0.071 0.15± 
0.05
0.644 1.14± 
0.15
0.052 0.04± 
0.02
0.071 7.20± 
1.84
0.398 8.10± 
1.86
0.171 0.30± 
0.20
0.055
Key: Cho, choline; Cr, creatine; mI, myo-inositol; mmol/kg, millimole per kilogram per brain tissue; NAA, N-acetyl-aspartate; r, Pearson correlation coefficient; ↑, significant increase compared to control; ↓, significant decrease compared to 
control; *indicates p<0.05, **p<0.01.
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NAA (p=0.049) and a trend to higher mI 
(p=0.074) compared to normal controls. 
There were significant increases in mI/Cr 
(p=0.004) and mI/Cho (p=0.006), and decre-
ase in NAA/Cho (p=0.028) in the left hippo-
campus. In the right hippocampus, there was a 
significant decrease of NAA/Cr (p=0.010) and a 
trend of significant increase in mI/Cr (p=0.067) 
while the other metabolite ratios in bilateral 
hippocampi showed no significant difference. 
Mean absolute concentrations of metabolites 
and metabolite ratios in NS+ patients 
In the left hippocampus, NS+ patients showed 
significantly higher Cho (p=0.005), Cr (p=0.002) 
and mI (p=0.003) compared to normal con-
trols. In the right hippocampus, NS+ patients 
showed significantly lower NAA (p=0.029) com-
pared to normal controls. 
There were significant decrease in NAA/Cr 
(p=0.037) and NAA/Cho (p=0.009), and signifi-
cant increase in mI/Cr (p=0.003) and mI/Cho 
(p=0.005) in the left hippocampus, as well as a 
significant decrease in NAA/Cr (p=0.013) and a 
significant increase in mI/Cho in the right hip-
pocampus (p=0.048), while the other metabo-
lite ratios in bilateral hippocampi showed no 
significant difference. 
Mean absolute concentrations of metabolites 
and metabolite ratios in non-HIV, non-NS 
patients
In the bilateral hippocampi, non-HIV, non-NS 
patients showed no significant difference in 
absolute concentration or metabolite ratio 
compared to normal controls, except increased 
Cho/Cr (p=0.049) in the left hippocampus after 
adjustment for age. 
Discussion
It was recognized that HIV infection is associ-
ated with an increased risk of NS, especially 
early NS [16], and clearance of NS is problem-
atic in HIV infected patients with low CD4 
counts and uncontrolled viral load [18]. 
However, the extent of brain damage associat-
ed with concomitant infections has been defi-
cient in the literature. We were first to demon-
strate in a cohort of syphilitic patients, mixed 
HIV infection and NS cause substantial meta-
bolic changes in the bilateral hippocampi, 
despite a paucity of MRI abnormalities in the 
structural scans.
In a neuroimaging study of 35 NS patients with 
a majority being HIV+ (91%), Brightbill et al. [12] 
found that cortical atrophy, cerebral infarc-
tions, non-specific white matter lesions and 
arteritis occur in 37%, 23%, 7% and 2% of the 
patients respectively. Another study [24] of 14 
HIV- NS patients detected cortical atrophy, 
cerebral infarctions, non-specific white matter 
lesions and arteritis in 50%, 43%, 50% and 
29% respectively. In our cohort of 25 syphilitic 
patients (28% being HIV+ NS, 24% being HIV+ 
only, 20% being NS only, and 28% without HIV 
and NS), cortical atrophy, cerebral infarctions, 
non-specific white matter lesions (Fazekas’ 
score- 2 or 3) and arteritis were present in 32%, 
4%, 12% and 0% respectively. 
The MRI findings indicated that the HIV+ or NS+ 
patients in our cohort did not have advanced 
structural disease. However, complex metabol-
ic abnormalities were already demonstrated in 
both HIV+ and NS+ patients. In addition, these 
patterns revealed striking similarities, which 
could possibly be due to partial overlapping of 
patients in the subgroups, and/or the promo-
tion of syphilitic CNS involvement in HIV-related 
immunocompromise [6, 7, 13-17]. 
In our cognitively normal HIV+ group (only 3 on 
HAART due to low CD4 count), we found signifi-
cant increases in absolute concentrations of 
Cho, and mI, and metabolite ratios of mI/Cr and 
mI/Cho, and decreased NAA/Cho in left hippo-
campus, as well as decreases in absolute con-
centration of NAA and NAA/Cr, and a trend of 
increase in mI/Cr in the right hippocampus. 
Therefore, our hippocampal results were simi-
lar to previous studies of asymptomatic HIV 
subjects in the subcortical white matter/thala-
mi [28-30, 32, 35]. Increased mI (or mI/Cr) and 
Cho (or Cho/Cr) in HIV+ patients have been 
attributed to increased glial activity and were 
found to increase with advancing ADC stages 
[1], and reflected the presence of inflammatory 
changes [33]. 
Contrary to a previous study [38], we found no 
significant change in Cho/Cr in the hippocampi 
of HIV+ group. The lack of significance could 
have been caused by the concomitant increas-
es in absolute concentrations of the 2 metabo-
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lites [1]. Therefore, quantification based on rel-
ative ratios of metabolites using Cr as reference 
has its drawbacks and could be misleading [1, 
44].
Our finding of increase in Cr was contradictory 
to a prior study [30], which detected a decrease 
in Cr. However, their neurologically asymptom-
atic HIV patients were either Category B or C 
according to CDC classification, and likely be 
associated with impairment of energy metabo-
lism. Nevertheless, HIV-dementia patients had 
shown both an increase and a decrease in Cr 
concentrations [1, 40] and the controversial 
role of Cr has not been resolved. 
NAA decrement was found in moderate to 
severe ADC stages [1, 34], as well as mild 
degree of lowered N-acetyl-aspartate/creatine 
(NAA/Cr), or N-acetyl-aspartate/choline (NAA/
Cho) or both in the subcortical white matter of 
asymptomatic HIV+ patients [28-30]. These 
reductions might represent early neuronal 
damage without gross anatomical abnormali-
ties. An autopsy study [25] had shown that the 
HIV load in AIDS was not distributed uniformly, 
but showed higher levels in the basal ganglia 
and hippocampus than mid-frontal cortical gray 
matter. Hence, it was not surprising to detect 
lower NAA in the right hippocampus of our HIV+ 
group. We postulated that metabolic changes 
in HIV patients might occur early in the hippo-
campi, not being described previously in the 
literature. Moreover, interaction between NS 
and HIV might also be a factor.
In the NS+ group, significantly increased abso-
lute concentrations of Cho, Cr and mI, dec- 
reased NAA/Cr and NAA/Cho and increased 
mI/Cr and mI/Cho in left hippocampus, and sig-
nificantly decreased NAA and NAA/Cr and 
increased mI/Cho in right hippocampus were 
found. There is an increased awareness of 
mesial temporal T2 signal abnormalities in NS 
[21-24], but the etiology is still uncertain. 
Elevated inflammatory biomarkers such as Cho 
and mI in our study supported the hypothesis 
postulating that the signal change was due to a 
combination of edema and gliosis [21, 23]. 
In the current study, the profound metabolic 
changes in HIV+ and NS+ groups were in 
marked contradistinction from the ‘negative’ 
metabolic results in the non-HIV, non-NS group 
(except elevated Cho/Cr with borderline signifi-
cance). The non-HIV, non-NS group comprised 
of 7 late latent syphilitic patients with neuro-
logical symptoms or persistently elevated VDRL 
titer after treatment, thereby mimicking NS 
clinically. 
From the clinical standpoint, it is necessary to 
exclude NS in syphilitic patients at greatest 
risk, and some authorities suggested perform-
ing lumbar puncture on all patients with HIV 
and syphilis [6]. 1H-MRS might serve as a non-
invasive test for triaging patients with reactive 
syphilitic serology and neurological symptoms 
and signs suspicious of NS to undergo lumbar 
puncture or not. 1H-MRS is rendered useless in 
patients with HIV co-infection as the metabolic 
changes overlap with NS. In HIV- patients, our 
results showed that 1H-MRS could potentially 
rule out NS in such a group of patients. 
Validation of our results by a larger scale study 
is warranted.
Furthermore, similar to its use in evaluation of 
HAART in HIV [40, 41], future studies are envis-
aged to explore the role of 1H-MRS in monitor-
ing response of NS to treatment, by evaluation 
of normalization of the inflammatory metabo-
lite markers such as mI and Cho. 
The major limitation of our study was a small 
cohort size. Also, the patients within HIV+ sub-
group were in varying stages of syphilitic dis-
ease and some were under HAART treatment. 
Similarly, four of the patients in the NS+ sub-
group were under treatment. The complex 
interactions between NS and HIV should be elu-
cidated in a future large cohort study by com-
paring exclusive HIV and NS subgroups with 
mixed HIV/NS subgroup, preferably before drug 
treatment.
In conclusion, patients with mixed HIV infection 
and NS were found to have substantial meta-
bolic changes in bilateral hippocampi, despite 
the paucity of MRI abnormalities in the struc-
tural scans. Striking similarities in the complex 
metabolic patterns in mixed HIV infection and 
NS were demonstrated in the current study, 
suggesting potential interactions between the 
two diseases. Finally, 1H-MRS holds promise to 
identify NS in non-HIV patients with reactive 
syphilitic serology and neurological symptoms.
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